天臣医疗(688013) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for the reporting period reached RMB 326,736,247.45, an increase of 19.96% compared to the previous year[3] - Operating profit was RMB 94,237,898.44, reflecting a year-on-year growth of 71.35%[3] - Net profit attributable to shareholders of the parent company was RMB 84,092,590.88, up 62.04% from the previous year[3] - Basic earnings per share increased to RMB 1.05, representing a growth of 61.54%[3] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 672,845,043.11, a 5.59% increase from the beginning of the period[3] - The company's equity attributable to shareholders of the parent company decreased by 2.92% to RMB 564,456,295.51[3] Strategic Initiatives - The company attributed the increase in profits to its innovation-driven strategy and stable sales growth of endoscopic staplers[8] - The gross profit margin improved due to economies of scale and cost optimization efforts[8] - Foreign exchange gains from currency fluctuations contributed positively to the financial results during the reporting period[8] - The company is actively adjusting its marketing strategy and expanding into overseas markets to enhance competitiveness[7]